Your browser version may not work well with NCBI's Web applications. More information here...
1: Endocrinology. 2007 Mar;148(3):936-41. Epub 2006 Aug 31.Click here to read Links

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Ciampi R, Nikiforov YE.

Department of Pathology, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA.

Thyroid papillary carcinoma is the most common type of endocrine cancer. It is frequently associated with genetic alterations leading to activation of the MAPK signaling pathway. The two most frequently affected genes, BRAF and RET, are activated by either point mutation or as a result of chromosomal rearrangement. These mutations are tumorigenic in thyroid follicular cells and correlate with specific phonotypical features and biological properties of papillary carcinomas, including tumor aggressiveness and response to radioiodine therapy. Molecular inhibitors that block RET/PTC or BRAF kinase activity have shown substantial therapeutic effects in the experimental systems and are currently being tested in clinical trials.

PMID: 16946010 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Thyroid (Armour® Thyroid)

    Thyroid is a hormone produced by the body. When taken correctly, thyroid is used to treat the symptoms of hypothyroidism (a condition where the thyroid gland does not produce enough thyroid hormone). Symptoms of hypothyr...

  • Source: AHFS Consumer Medication Information